Filter by: Subject

Filter by: Subject

Results Per Page:

Prostate cancer (6)
Prostate-specific membrane antigen (PSMA) (6)
Positron emission tomography/computed tomography (PET/CT) (5)
Positron emission tomography (PET) (4)
Patients (3)
Prostate carcinoma (3)
South Africa (SA) (3)
Tuberculosis (TB) (3)
177Lu-PSMA (2)
68Ga-PSMA (2)
Actinium-225 (2)
Cervical cancer (2)
Hypoxia (2)
Immunohistochemistry (2)
Metastatic castration-resistant prostate cancer (mCRPC) (2)
PET/CT (2)
Radioligand therapy (2)
Theranostics (2)
18F-FDG (1)
18F-FDG PET/CT (1)
18F-fluorodeoxyglucose (18F-FDG) (1)
225Ac-PSMA-617 (1)
68Ga-citrate (1)
68Ga-citrate PET/CT (1)
68Ga-DKFZ-PSMA-11 (1)
68Ga-HBED-CC-(Ahx)Lys-NH-CO-NH-Glu (1)
68Ga-Nitroimidazole (1)
68Ga-PSMA PET/CT (1)
68Ga-PSMAHBED (1)
[68Ga]Ga-FAPI PET/CT (1)
[68Ga]Ga-NODAGAZOL (1)
[68Ga]Ga-PSMA-11 (1)
[99mTc]Tc-MDP (1)
Angiotensin-converting enzyme 2 (ACE2) (1)
Bismuth-213 (1)
Black South-African (BSAs) (1)
Bone scan (1)
Breast cancer (1)
Breast uptake (1)
Burkitt lymphoma (BL) (1)
Cardiac implantable electronic device (CIED) (1)
Cavernous sinus syndrome (1)
Chemotherapy-naïve (1)
Computed tomography (CT) (1)
Computerized tomography (CT) (1)
Coronavirus disease 2019 (COVID-19) (1)
COVID-19 pandemic (1)
Cytokine storm (1)
Endoradiotherapy (1)
Epigenetics (1)
FAPI tumor volume (FAPI-TV) (1)
Fluorine-18 2-fluoro-2-deoxyglucose (18F-FDG) (1)
Fluorine-18 fluorodeoxyglucose (1)
Fluorine-18-fluorodeoxyglucose (18F-FDG) (1)
Hypoxia inducible factor-1 (HIF-1) (1)
Hypoxia-inducible factor-1alpha (HIF-1) (1)
Hypoxic tumor volume (HTV) (1)
Imaging technology (1)
Infective endocarditis (1)
Left ventricular assist device (1)
Lung lesions (1)
Menstrual cycle (1)
Metabolic tumor volume (MTV) (1)
Metastasized castration-resistant prostate cancer (mCRPC) (1)
Metastatic castrate-resistant prostate cancer (1)
Metastatic prostate carcinoma (1)
Morbidity (1)
Mortality (1)
Multi-organ (1)
Neuroendocrine tumour (NET) (1)
Overall survival (OS) (1)
Patient management (1)
Patient treatment (1)
Peptide receptor radionuclide therapy (PRRT) (1)
PET/computed tomography (1)
Positron emission tomography/computed tomography (PET/CT) (1)
Primary prostate carcinoma (PPC) (1)
Pro-inflammatory cytokines (1)
Progression-free survival (PFS) (1)
Prostate specific membrane antigen (PSMA) (1)